DRG Market Assessment 보고서

How Does Cost versus Dosing Impact Prescriber Preferences and Payer Policy? The prevalence of age-related macular degeneration (AMD) is increasing with the aging population in China. Therapies…

Biologics prescribed by rheumatologists and gastroenterologists are among the most commercially successful biopharmaceutical products in the world. These biologics are a prime target for biosimilar…

Last Updated 28 September 2015 The market for Alzheimer’s disease (AD) pharmacotherapies offers enormous commercial opportunity driven by considerable unmet need and looming societal burden. The…

Dyslipidemia is a risk factor for the development of cardiovascular disease and one of the most prevalent diseases in the United States. The efficacy of statins has led to their dominance in the…

Medical device companies developing products for drug-treated populations must understand the clinical, health economic, and marketing challenges that manifest from this convergence, or risk their…

How Are Payer Strategies and Prescriber Preferences Shaping the Non-Insulin Treatment Algorithm? Although a high opportunity market, the therapeutic space for type 2 diabetes (T2D) is set to…

Increasing formulary competition and decreasing product differentiation have led to an aggressive pricing war in the U.S. asthma and chronic obstructive pulmonary disorder (COPD) markets. As…

Gastric and gastroesophageal junction (GEJ) adenocarcinoma is characterized by poor prognosis. Japan has the highest incidence of gastric and GEJ adenocarcinoma among the markets under study,…

Gram-negative pathogens (GNPs) are clinically important pathogens in both the hospital and outpatient settings. GNPs are often acquired in healthcare facilities, and therefore have a high incidence…

For regenerative medicine to truly deliver on its potential, one important stakeholder, medical device companies, have to come to grips with the increasing role of regenerative medicine in patient…

The ovarian cancer therapy market retains its potential for commercial reward for drug developers. Although the disease tends to respond well initially to chemotherapy and current drug treatment…

LaunchTrends: Entyvio Wave 3 (US) measures the impact of this novel agent on the moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) market one year following launch. The report…